Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0134
+0.0002 (1.52%)
At close: Nov 16, 2026
Oncotelic Therapeutics Employees
As of December 31, 2025, Oncotelic Therapeutics had 43 total employees, including 38 full-time and 5 part-time employees. The number of employees increased by 13 or 43.33% compared to the previous year. That makes Oncotelic Therapeutics the 35,719th largest employer in the world and 4,816th in the United States.
Employees
43
Change (1Y)
13
Growth (1Y)
43.33%
Revenue / Employee
$6,098
Profits / Employee
$6,036,465
Market Cap
6.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 43 | 13 | 43.33% | 38 | 5 |
| Dec 31, 2024 | 30 | 8 | 36.36% | 26 | 4 |
| Dec 31, 2023 | 22 | 0 | - | 22 | 0 |
| Dec 31, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Dec 31, 2021 | 16 | 0 | - | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptimmune Therapeutics | 272 |
| Orgenesis | 77 |
| Zeo ScientifiX | 33 |
| OSR Health | 22 |
| Reviva Pharmaceuticals Holdings | 14 |
| America Great Health | 5 |
Oncotelic Therapeutics News
- 14 days ago - 3 Hot Stocks with Recent Insider Buying - TipRanks
- 21 days ago - Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature - GlobeNewsWire
- 27 days ago - Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery - GlobeNewsWire
- 6 weeks ago - PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026 - GlobeNewsWire
- 3 months ago - Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th - GlobeNewsWire
- 3 months ago - Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) - GlobeNewsWire
- 4 months ago - Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway - GlobeNewsWire
- 4 months ago - Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003 - GlobeNewsWire